Highest-materiality recent filing
Palisade Bio appoints Jordan Zwick to board; shareholders approve 50% share increase to 450M
Jordan Zwick appointed to board, effective June 10, 2026; board expanded from five to six members.
Palisade Bio Q1 2026: Cash $132.6M; R&D spend up 6.4x; PALI-2108 Phase 2 UC starts Q3 2026
Cash and equivalents of $132.6M at March 31, 2026, sufficient through Phase 2 UC readout (2H 2027) and CD readout (early 2028).
Palisade Bio signs enrollment deal with Iterative Health, issues $3M stock to affiliate
Entered MSA with Iterative Health to assist with patient enrollment for Phase 2 study of PALI-2108 in ulcerative colitis.
Authorized common stock increased from 280M to 300M shares via certificate of amendment filed Dec. 3, 2025.
Phantom Unit Plan adopted Sept 4, 2025 terminated Oct 22, 2025.
Palisade Bio shareholders approve reverse stock split of 1:5 to 1:50, board to decide ratio
Three directors re-elected: J.D. Finley (647,086 votes for), Donald Williams (641,789), Emil Chuang (659,895); each had 2,849,169 broker non-votes.
Palisade Bio regains Nasdaq minimum bid price compliance; reports $133.3M cash
Received Nasdaq compliance letter confirming regained bid price requirement; matter closed as of Oct 15, 2025.
Palisade Bio cancels special stockholder meeting, withdraws proposals due to lack of quorum
Special meeting scheduled for Oct. 10, 2025 cancelled after failure to achieve quorum at prior adjournments.
Palisade Bio adjourns special meeting due to lack of quorum; reconvenes Oct 10
Special meeting on Sep 26, 2025 lacked quorum, adjourned without conducting business.
Palisade Bio adjourns special meeting due to lack of quorum; reconvenes Sept 26, 2025
Special meeting of stockholders convened Sept 18, 2025, adjourned without business due to insufficient quorum.
Phantom Unit Plan approved; up to 10,000,000 cash-settled phantom units may be granted.
Palisade Bio announces $3.9M warrant exercise; issues new warrants for up to 8.6M shares
Existing warrant holders exercised 4,318,905 shares at reduced price $0.9047 (from $1.40); gross proceeds ~$3.9M.
Palisade Bio appoints Emil Chuang to board; Fischbein resigns
Margery Fischbein resigned from board effective July 2, 2025; no disagreement with company.
Palisade Bio receives Nasdaq deficiency notice for bid price below $1.00
Notice dated April 30, 2025, due to bid price closing below $1.00 for 30 consecutive trading days.
Palisade Bio Closes $5M Underwritten Public Offering of Units and Warrants
Issued 158,000 Class A Units (common + warrant) and 3,120,688 Class B Units (prefunded warrant + warrant) at $1.525/$1.5249 per unit.
Palisade Bio revises CEO/CFO J.D. Finley's employment agreement; salary unchanged
Base salary stays at $542,000 per year; target bonus remains up to 50% of base.
Palisade Bio stockholders elect directors and ratify Baker Tilly as auditor at annual meeting
J.D. Finley elected director: 141,074 votes for, 11,984 withheld, 227,228 broker non-votes.
Palisade Bio appoints Margery Fischbein to Board of Directors
Margery Fischbein appointed to the Board effective May 7, 2024; increases Board to 4 directors.
Palisade Bio announces $4M private placement of common stock and pre-funded warrants
Gross proceeds of $4M from sale of 615,242 shares/pre-funded warrants at $6.5015 each.
Palisade Bio details PALI-2108 development for ulcerative colitis at IBD conference
PALI-2108 is a colon-specific PDE4 inhibitor prodrug for moderate-to-severe ulcerative colitis.
Palisade Bio completes 1-for-15 reverse stock split to meet Nasdaq minimum bid price
1-for-15 reverse split effective April 5, 2024; shares reduced from 12,771,015 to ~851,401.
Palisade Bio FY2023 net loss $13.1M; Nasdaq audit committee shortfall; reverse split approved
Cash and equivalents $12.5M at Dec 31, 2023; sufficient to fund operations into Q1 2025.
Palisade Bio director Mary Ann Gray resigns; board adopts declassified structure
Director Mary Ann Gray resigned effective March 4, 2024, with no disagreement with company.
Palisade Bio reduces board from 8 to 4; four directors resign, Chairman changed
Directors James Neal, Stephanie Diaz, Cristina Csimma, Robert Trenschel resigned immediately; no disagreement cited.
Palisade Bio exercises warrants for $2.5M gross proceeds; exercise price reduced to $0.7313
Exercise of ~3.4M Existing Warrants at reduced price of $0.7313 per share, raising ~$2.5M gross.
Palisade Bio reports positive preclinical data for PALI-2108 UC therapy; Phase 1 planned for 2024
PALI-2108 showed colon-selective bioactivation with colon/plasma AUC ratio >200.
Palisade Bio updates corporate presentation; no material new information disclosed
Palisade Bio filed an 8-K on November 7, 2023, attaching an updated corporate presentation.
Palisade Bio receives Nasdaq notice for bid price below $1.00 per share
Nasdaq notified Palisade Bio on Oct 19, 2023 of non-compliance with $1.00 minimum bid price rule.
Palisade Bio raises $1.97M in registered direct offering of 2.34M shares at $0.84/share
Gross proceeds of approximately $1.97 million from sale of 2,339,398 shares at $0.84 per share.
Palisade Bio appoints Mitchell Jones as CMO; grants inducement options and RSUs
Mitchell Jones, M.D., Ph.D., appointed Chief Medical Officer effective Sept 5, 2023.
Palisade Bio licenses Giiant Pharma's oral IBD drug candidates GT-2108 and GT-1908
Exclusive worldwide license for Giiant's targeted prodrug platform; lead asset GT-2108 for ulcerative colitis.
Palisade Bio CEO gets pay raise; shareholders OK equity plan amendments increasing shares
CEO J.D. Finley's base salary raised to $542,000 from $490,000; bonus target increased to 50% from 45%, effective June 1, 2023.
Palisade Bio raises $6M in registered direct offering and private placement at $2.64/share
Gross proceeds of ~$6.0M from sale of 2,272,723 shares/pre-funded warrants at $2.64 per share.
Palisade Bio confirms no deposits or investments at Silicon Valley Bank
Company aware of FDIC takeover of SVB due to liquidity concerns.
Palisade Bio promotes Robert McRae to COO, appoints J.D. Finley to Board
Robert McRae appointed COO effective Feb 2, 2023; previously SVP of Operations and Strategic Development.
Palisade Bio closes $2.5M registered direct offering and concurrent private placement
Raised approximately $2.5M gross via 1,052,631 shares/pre-funded warrants at $2.375/share plus 1,052,631 five-year warrants at $2.375.
Palisade Bio stops Phase 2 LB1148 trial early; topline data due H1 2023
Enrolled 35 of 70 planned patients in Phase 2 PROFILE study for post-surgical adhesions; voluntarily halting further enrollment.
Palisade Bio appoints Dr. Herbert Slade as Chief Medical Officer effective Nov 17, 2022
Dr. Slade will serve as part-time consultant CMO with annual compensation of $240,000.
Palisade Bio effects 1-for-50 reverse stock split to meet Nasdaq minimum bid price
Reverse split effective 5:00 p.m. ET Nov 15, 2022; common stock trades on split-adjusted basis from Nov 16 under same ticker PALI.
Palisade Bio terminates Chief Medical Officer Michael Dawson, effective Oct 11, 2022
Michael Dawson, MD, terminated as Chief Medical Officer effective October 11, 2022.
Palisade Bio CEO Thomas Hallam resigns; CFO JD Finley appointed interim CEO
CEO Thomas Hallam resigned effective Oct 11, 2022; separation agreement includes $530,000 paid over 12 months, COBRA, accelerated vesting.
Reverse split ratio range 1-for-10 to 1-for-50 approved at Oct 4 special meeting; 45.2M votes for, 2.9M against.
Palisade Bio dismisses BDO as auditor, appoints Baker Tilly effective Sept 21, 2022
Audit committee dismissed BDO USA, LLP on Sept 21, 2022; no disagreements during 2020-2021 or interim 2022.
Reduction in force of 20% with estimated cash severance of $380,148.
Gross proceeds ~$13.8M; net proceeds ~$12.2M after underwriting discounts and estimated expenses.
Palisade Bio reduces stockholder meeting quorum requirement from majority to one-third
Board adopted amended bylaws on Aug 10, 2022 to lower quorum to one-third of outstanding common shares.
Palisade Bio shareholders elect two Class II directors and ratify auditor at 2022 annual meeting
Election of Donald Williams and Robert J. Trenschel as Class II directors to serve until 2025.
Palisade Bio receives Nasdaq bid price deficiency notice; 180 days to regain compliance
Nasdaq notified on May 20, 2022 that PALI common stock closed below $1.00 minimum for 30 consecutive trading days.
Palisade Bio raises $2.0M via registered direct offering and warrants
3,646,690 shares at $0.55/share for gross proceeds of ~$2.0M.
Palisade Bio raises ~$2.0M in registered direct offering and warrants
Sold 3,646,690 shares at $0.55/share for gross proceeds of ~$2.0M.
On June 10, 2026 (the “Effective Date”), the Board of Directors (the “Board”) of Palisade Bio, Inc. (the “Company”) expanded the size of the Board from five to six directors and appointed Jordan Zwick to the Board.
On May 7, 2024 (the “Effective Date”), the board of directors (“Board”) of Palisade Bio, Inc. (the “Company”) appointed Margery Fischbein to the Board.
On March 4, 2024, Mary Ann Gray, Ph.D. informed the board of directors (“Board”) of Palisade Bio, Inc. (the “Company”) that she is resigning as a member of the Board effective immediately.
James Neal, Stephanie Diaz, Dr. Cristina Csimma, and Dr. Robert Trenschel (collectively, the “Resigning Directors”), informed the board of directors (“Board”) of Palisade Bio, Inc. (the “Company”) that each is resigning as a member of the Board effective immediately.
James Neal, Stephanie Diaz, Dr. Cristina Csimma, and Dr. Robert Trenschel (collectively, the “Resigning Directors”), informed the board of directors (“Board”) of Palisade Bio, Inc. (the “Company”) that each is resigning as a member of the Board effective immediately.
James Neal, Stephanie Diaz, Dr. Cristina Csimma, and Dr. Robert Trenschel (collectively, the “Resigning Directors”), informed the board of directors (“Board”) of Palisade Bio, Inc. (the “Company”) that each is resigning as a member of the Board effective immediately.
James Neal, Stephanie Diaz, Dr. Cristina Csimma, and Dr. Robert Trenschel (collectively, the “Resigning Directors”), informed the board of directors (“Board”) of Palisade Bio, Inc. (the “Company”) that each is resigning as a member of the Board effective immediately.
Mitchell Jones, M.D., Ph.D. (“Dr. Jones”) has been appointed Chief Medical Officer effective September 5, 2023
On February 2, 2023, the Company appointed Robert McRae as the Company’s Chief Operating Officer.
On February 2, 2023, the Board appointed J.D. Finley to the Board.
On November 17, 2022, the Board of Directors of Palisade Bio, Inc. (“Company”) appointed Herbert B. Slade, MD FAAAAI, to serve as the Company’s chief medical officer.
the employment of Michael Dawson, MD, was terminated by Palisade Bio, Inc.
Max materiality 0.75 · Median 0.57 · Most common event other_material